EBRC In Translation EBRC SPA

In this episode we’re joined by Eldora Ellison, PhD, director at law firm Sterne Kessler and lead patent strategist for the CVC group in the MIT-Berkeley CRISPR patent litigation. We discuss the long and winding road of filing and defending patents, what it’s like to go from PhD scientist to law firm partner, how biotechnology advances are challenging the world of patents, and more!
Links related to the episode:
Careers at Sterne Kessler
U.S. Biotechnology Patent Law by Jorge Goldstein

In this episode, we interview Vineeta Agarwala, MD, PhD, a general partner at Andreesen Horowitz (a16z) where she leads investments in the group’s bio + health fund. We talk to Vineeta about investing in synthetic biology startup companies, a day in the life of a VC, following the good people, and more!


Disclosures:
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

In this episode, we interview Dr. Henry Lee, CEO of Cultivarium, a focused research organization that aims to expand access to novel microorganisms. We discuss the world’s fastest-growing bacterium, the challenges of domesticating non-model microbes, new organizational models for science, robotic dogs, and more!

If you are interested in Cultivarium, you can learn more and get involved at https://www.cultivarium.org/.

In this episode, we interview Dr. Doug Friedman, CEO of the BioIndustrial Manufacturing and Design Ecosystem (BioMADE) and President of the Engineering Biology Research Consortium (EBRC). We talk about how to build and grow community-driven organizations, what it takes to be an expert in DC, visions for the future of the bioeconomy, and more!

For more information about EBRC, visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

In this episode, we interview Dr. Hana El-Samad, a Professor at UCSF, editor-in-chief of GEN biotechnology, and a founding PI at Altos labs, whose research focuses on controlling mammalian cell behavior with genetic circuits. We talk with Dr. El-Samad about her work on controlling mammalian cell behavior, her role at and transition to Altos labs, committing to equity in STEM, the mission of GEN biotechnology, and more!

For more information about EBRC, visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!
Notes and links:
Fund Black Scientists
Director Lander, the time is now

In this episode, we interview Dr. Ross Cloney, a Senior Editor at Nature Communications, focusing on the areas of synthetic biology, genome engineering, and therapeutic biotechnology. We talk with Ross about: how a manuscript becomes a publication; what it’s like to be an editor; how to make scientific publishing more diverse, equitable, and inclusive; what the future of scientific journals looks like; and more!
For more information about EBRC, visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!